ArticleScientific reports2017
GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Citronellol silver nanoconjugates as a therapeutic strategy for glioblastoma through computational and experimental evaluation.Scientific reports · 2025Article
- Carfilzomib inhibits the progression of hepatocellular cancer by upregulating GADD45α expression.Oncology letters · 2025Article
- Cellular and molecular antiproliferative effects in 2D monolayer and 3D-cultivated HT-29 cells treated with zerumbone.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- A ferrocene-containing nucleoside analogue targets DNA replication in pancreatic cancer cells.Metallomics : integrated biometal science · 2022Article
- Thallium Induces Antiproliferative and Cytotoxic Activity in Glioblastoma C6 and U373 Cell Cultures via Apoptosis and Changes in Cell Cycle.Neurotoxicity research · 2022Article
- Roles for GADD45 in Development and Cancer.Advances in experimental medicine and biology · 2022Review
- Article
- A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells.Molecules (Basel, Switzerland) · 2021Article
- Anti-tumour activity of deer growing antlers and its potential applications in the treatment of malignant gliomas.Scientific reports · 2021Article
- Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- Considering the Experimental use of Temozolomide in Glioblastoma Research.Biomedicines · 2020Review
- Combined Use of Three Machine Learning Modeling Methods to Develop a Ten-Gene Signature for the Diagnosis of Ventilator-Associated Pneumonia.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.Journal of experimental & clinical cancer research : CR · 2019Article
- Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.International journal of molecular sciences · 2019Article
- GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status.OncoTargets and therapy · 2019Article
- Overexpression of COX7A2 is associated with a good prognosis in patients with glioma.Journal of neuro-oncology · 2018Article
- Identification ofCancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive cancers. Despite recent advances in multimodal therapies, high-grade glioma remains fatal. Temozolomide (TMZ) is an alkylating agent used worldwide for the clinical treatment of GBM; however, the innate and acquired resistance of GBM limits its application. Here, we found that TMZ inhibited the proliferation and induced the G2/M arrest of GBM cells. Therefore, we performed microarrays to identify the cell cycle- and apoptosis-related genes affected by TMZ. Notably, GADD45A was found to be up-regulated by TMZ in both cell cycle and apoptosis arrays. Furthermore, GADD45A knockdown (GADD45A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.